Details of the Drug Combination

General Information of Drug Combination (ID: DCMYP1Y)

Drug Combination Name

Amifostine Carboplatin

Indication

Disease Entry	Status	REF
Chemotherapeutic Agent Toxicity	Phase 2	[1]

Component Drugs

Amifostine DM5FL14

Carboplatin DMG281S

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Amifostine

Disease Entry	ICD 11	Status	REF
Mucositis	CA00	Approved	[2]

Amifostine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Toxic reactive metabolite (TRM)	TT0C9DV	NOUNIPROTAC	Modulator	[2]
------------------------------------------------------------------------------------

Amifostine Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Alkaline phosphatase (ALPL)	DEVEFKM	PPBT_HUMAN	Metabolism	[5]
------------------------------------------------------------------------------------

Amifostine Interacts with 7 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Etoposide-induced protein 2.4 homolog (EI24)	OTD4NOYS	EI24_HUMAN	Decreases Expression	[6]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Activity	[7]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Phosphorylation	[7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Decreases Expression	[6]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Decreases Expression	[6]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Increases Localization	[8]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Decreases Expression	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DOT(s)

Indication(s) of Carboplatin

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[3]
Carcinoma	2A00-2F9Z	Approved	[3]
Cholangiocarcinoma	2C12.10	Approved	[3]
Cutaneous melanoma	2C30	Approved	[3]
Epithelial ovarian cancer	2B5D	Approved	[3]
Fallopian tube neoplasm	N.A.	Approved	[3]
Gastroesophageal junction adenocarcinoma	2B71	Approved	[3]
Lung adenocarcinoma	N.A.	Approved	[3]
Lung cancer	2C25.0	Approved	[3]
Non-small-cell lung cancer	2C25.Y	Approved	[3]
Ovarian cancer	2C73	Approved	[4]
Ovarian disorder	N.A.	Approved	[3]
Ovarian neoplasm	N.A.	Approved	[3]
Ovarian serous cystadenocarcinoma	N.A.	Approved	[3]
Small-cell lung cancer	2C25.Y	Approved	[3]
Lung large cell carcinoma	N.A.	Investigative	[3]
Neuroblastoma	2D11.2	Investigative	[3]

Carboplatin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[9]
------------------------------------------------------------------------------------

Carboplatin Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
High affinity copper uptake protein 1 (SLC31A1)	DTP8L4F	COPT1_HUMAN	Substrate	[10]
------------------------------------------------------------------------------------

Carboplatin Interacts with 7 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Glutathione S-transferase pi (GSTP1)	DEK6079	GSTP1_HUMAN	Metabolism	[11]
Glutathione S-transferase theta-1 (GSTT1)	DE3PKUG	GSTT1_HUMAN	Metabolism	[11]
Metallothionein-1A (MT1A)	DE5ME8A	MT1A_HUMAN	Metabolism	[11]
Metallothionein-2A (MT2A)	DEFKGT7	MT2_HUMAN	Metabolism	[11]
Myeloperoxidase (MPO)	DEA3U9Y	PERM_HUMAN	Metabolism	[11]
Quinone reductase 1 (NQO1)	DENP5RY	NQO1_HUMAN	Metabolism	[11]
Glutathione S-transferase mu-1 (GSTM1)	DEYZEJA	GSTM1_HUMAN	Metabolism	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DME(s)

References

1	ClinicalTrials.gov (NCT00095927) Randomized Amifostine For SCCHN
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Carboplatin FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
5	Pharmacokinetic profile of amifostine. Semin Oncol. 1996 Aug;23(4 Suppl 8):18-22.
6	Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther. 2003 Sep;2(9):893-900.
7	Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther. 2006 Aug;13(8):806-14. doi: 10.1038/sj.cgt.7700960. Epub 2006 Apr 21.
8	Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors. Blood. 1999 Dec 15;94(12):4060-6.
9	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
10	Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
11	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)